Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q2 2024 · 10-Q
Revenue$232.00K$232.00K— vs Q2 2023 Net Income-$5.63M-$5.63MN/M vs Q2 2023 EPS Diluted-$3.10-$3.10N/M vs Q2 2023 Operating Income-$5,722,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,429,000N/M Margins · derivedOperating margin-2466.4%
Net margin-2427.2%
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end